AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 8:25 PM ET UBS lowers Rapport Therapeutics price target to $64 from $71, keeps Buy AI-generated summary · Source: press report
Nasdaq: $RAPPDated operating evidenceFinancing and capital structureExecution risk

RAPP Stock Hub: Rapport Therapeutics News, RAP-219 and Financing

Rapport reported Q3 net loss of $40.235 million and operating cash use of $41.633 million. The September cash/investment balance was $395.029 million. Following completed October financing and November ATM use, the company separately estimates $815.4 million resources as of November 3 and funding through end-2029. RAP-219 remains investigational: next come open-label FOS safety data, pivotal epilepsy execution and the planned mania FDA discussion. Filed accounts. Later estimate and clinical plans.

Last updated: November 4, 2026Market reference: November 3, 2026 completed regular-session close $25.44, before November 4 Q3Financial period: quarter and nine months ended September 30, 2026; later financing separately datedCurrency: USD
Full research report · PDF
Rapport research updated November 4, 2026
26 pages. All twenty analytical chapters and nine historical analytical answers, including TARPγ8/AMPA biology, the randomized mania result and its limitations, FOS evidence, FOCUS pivotal execution, long half-life, LAI and RAP-641, complete Q3/9M accounts and cash flow, September versus later estimated resources, closed equity and private placement, final physical note settlement, ATM use, Tenacia, ownership, management, competition and dated scenarios. Daily price/volume chart with SMA 50/200 on page 2, five-pillar Health Score and eight complete current FAQ answers. Personal use only: redistribution prohibited.
Get the report (PDF)
Next company-guided clinical window
Q4 2026 – initial long-term open-label FOS safety data

The extension is separate from the controlled FOCUS 1 and FOCUS 2 pivotal trials, which are enrolling. Tenacia is recruiting in China after NMPA IND approval. Open-label follow-up and pivotal outcomes have different evidentiary roles. Source.

Q1 2027: planned mania FDA meeting. H1 2027: planned PGTCS Phase 3 start. H2 2027: two planned mania pivotal starts. These are company windows, not approval dates.
Rapport Therapeutics RAPP daily stock chart
Daily chart $RAPP. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

RAPP stock at a glance

Close – November 3
$25.44
Completed regular session before November 4 Q3
Price series in PDF, page 2
September cash and investments
$395.029M
Filed balance; restricted cash $0.105M separate
Source
November 3 resource estimate
$815.4M
Company estimate after later financing; not the September balance
Source
Q3 net loss / EPS
$40.235M / $0.84
GAAP loss; weighted common shares 47,768,633
Source
Q3 operating cash use
$41.633M
Nine-month operating use $96.149M
Source
October offerings net proceeds
About $410.7M
Public equity/PF warrants, notes and private placement; closed October 30
Source
Common shares – November 2
59,279,630
Actual cover count; warrants and note conversion separate
Source
Company funding outlook
Through end-2029
Forecast includes October/November financing and spending assumptions
Source

Where Rapport stands after Q3 and the completed financing

Q3 R&D was $34.316 million and SG&A $9.770 million, with no quarterly collaboration or product revenue. Operating loss was $44.086 million; interest income brought net loss to $40.235 million. Nine-month collaboration revenue was $20 million from Tenacia and net loss $116.707 million. Source.

September resources were $395.029 million excluding $0.105 million restricted cash. The later $815.4 million November 3 figure is an unaudited company estimate after financing, distinct from the filed September balance and not an exact interim cash bridge. Management forecasts funding through end-2029 with clinical-spending and financing assumptions. Source.

FOCUS 1 and FOCUS 2 are enrolling, while initial open-label extension data are expected Q4 2026. The company plans mania FDA discussions Q1 2027 and two pivotal starts H2 2027. RAP-641 IND clearance permits clinical development, with preliminary Phase 1 results expected H2 2027; it is not marketing approval. Source.

The constructive case

The completed financing supports continued clinical evidence generation. Randomized Phase 2 mania results and ongoing pivotal epilepsy enrollment provide reasons for further testing. Long-term exposure and a defined regulatory plan can clarify the program’s next stage.

The cautious case

A modest placebo-adjusted Phase 2 result requires pivotal replication and careful tolerability assessment. Multiple indications raise spending requirements. New common shares, warrants and physically settled notes affect ownership, while regulatory and commercial success remain uncertain.

Latest Rapport Therapeutics news

Nov 6, 2026

Rapport registers Phase 1 study of long-acting injectable RAP-219 in epilepsy

Rapport Therapeutics has registered a Phase 1 study, NCT07923097, evaluating the safety, tolerability and pharmacokinetics of RAP-219 formulated as a long acting injectable. The study is listed for epilepsy with an enrollment of 60 and an overall status of RECRUITING. The registration was first posted on ClinicalTrials.gov on 2026-11-06.

Nov 5, 2026

UBS lowers Rapport Therapeutics price target to $64 from $71, keeps Buy

UBS cut its price target on Rapport Therapeutics to $64 from $71. The bank kept its Buy rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 5, 2026

Guggenheim lowers Rapport Therapeutics price target to $66 from $70, keeps Buy rating

Guggenheim cut its price target on Rapport Therapeutics to $66 from $70. The firm kept its Buy rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 5, 2026

Wells Fargo lowers Rapport Therapeutics price target to $47, maintains Overweight rating

Wells Fargo cut its price target on Rapport Therapeutics to $47 from $50. The bank kept its Overweight rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 4, 2026

Rapport Therapeutics reports third quarter 2026 financials and provides business update

Rapport reported a net loss of $40.2 million for the third quarter of 2026, compared with $26.9 million a year earlier. R&D expense was $34.3 million versus $22.3 million, and SG&A expense was $9.8 million versus $7.7 million. The company held $395.0 million in cash, cash equivalents and short-term investments at September 30, 2026, and expects runway through the end of 2029.

Nov 3, 2026

Rapport Therapeutics to participate in upcoming investor conferences

Rapport Therapeutics management will participate in two upcoming investor conferences. A fireside chat at the Stifel 2026 Healthcare Conference in New York City is scheduled for Wednesday, November 11, 2026. A company presentation followed by a fireside chat at the Jefferies Global Healthcare Conference in London is scheduled for Monday, November 16, 2026. Live webcasts and replays will be available in the Investors section of the Company's website.

RAPP stock catalysts: long-term safety and pivotal development

  • October 30, 2026 – Equity, notes and private placement closed. Completed
  • November 4, 2026 – Q3 results and financing update. Reported
  • Q4 2026 – Initial FOS open-label long-term safety data. Company window
  • Q1 2027 – End-of-Phase 2 mania FDA discussion. Company plan
  • H1 2027 – PGTCS Phase 3 initiation. Company plan
  • H2 2027 – Two mania pivotal trial initiations. Company plan
  • Q3 2027 – RAP-219 LAI Phase 1 pharmacokinetics. Company data window
  • H2 2027 – RAP-641 preliminary Phase 1 results. Company data window

FOCUS 1/2 enrollment is ongoing rather than a future trial-start catalyst. Each indication and formulation has a separate evidentiary path. Source.

RAP-219 mania: what the positive Phase 2 result establishes

The 253-participant trial met its primary YMRS endpoint at week three with a 3.1-point placebo-adjusted difference, p=0.045, from reductions of 15.4 and 12.3 points. The prespecified CGI-BP mania-severity difference was 0.4, p=0.024. All treatment-emergent adverse events were mild or moderate, with no serious events; adverse-event discontinuation was 3.2% versus 0.8%. Source.

Statistical significance, absolute benefit, discontinuations and pivotal replication are separate questions. The planned FDA meeting and later Phase 3 starts do not constitute drug approval or proof of superiority to established mania treatments. The full report keeps the detailed Phase 2 interpretation and earlier epilepsy evidence. Source.

RAPP financing: closed transactions, cash flow and share claims

October offerings, including full underwriter options, closed on October 30: 9,761,905 public common shares, 1,190,476 pre-funded warrants and a separate 1,428,571-share private placement, plus $172.5 million notes principal. Estimated net proceeds total $410.7 million: equity $215.7 million, notes $166.8 million and private placement $28.2 million. A further 399,201 ATM shares generated approximately $10 million gross; the company specifies a $25.05 price. ATM price and financing update. Source.

Nine-month operating cash use was $96.149 million versus H1 $54.516 million, giving Q3 $41.633 million. Capex was $0.164 million in both cumulative periods, giving zero Q3 difference. Q3 investing inflow $51.064 million and financing inflow $1.711 million produced a positive $11.142 million cash/restricted movement after operating use. H1 comparison. Source.

Actual common shares were 48,088,413 September 30 and 59,279,630 November 2; weighted Q3 EPS shares were 47,768,633. Warrants, physically settled notes and employee awards are additional potential claims with different terms. Separately dated ATM disclosure is not assumed to be fully reflected in every earlier cover count. Source.

The 2.25% notes mature December 1, 2032, with initial conversion rate 37.3483 shares per $1,000, approximately $26.775 per share. The October 30 closing terms irrevocably fix conversion settlement in common shares, with cash only for fractions, and permit holder conversion before the contractual deadline without a share-price trigger. Initial full-principal conversion represents approximately 6.443 million shares. Issuer redemption and ownership limits have separate conditions. Executed indenture. Source.

Merlintrader Health Score · $RAPP

3.70out of 5
Balance sheet and runway · 30%4.5

September 30, 2026 cash and investments were $395.029 million, excluding $0.105 million restricted cash. After later financing, the company estimates $815.4 million resources November 3 and funding through end-2029. This is a company forecast with clinical-spending assumptions; the later $172.5 million convertible principal is separate from September liabilities.

Catalyst · 30%4.0

Initial long-term open-label FOS data are expected Q4 2026, FDA mania discussions Q1 2027 and PGTCS Phase 3 initiation H1 2027. Two mania pivotal starts target H2 2027, LAI pharmacokinetic data Q3 2027 and RAP-641 preliminary Phase 1 results H2 2027. FOCUS 1/2 are enrolling; these milestones do not guarantee efficacy or approval.

Dilution · 20%2.5

Actual common shares were 59,279,630 November 2, 2026 after October financing, compared with 48,088,413 September 30. New pre-funded warrants cover 1,190,476 shares and initial full-note conversion approximately 6.443 million shares, with physical settlement. A further 399,201 ATM shares are separately disclosed; awards and future issuance remain additional claims.

Liquidity · 10%3.0

RAPP closed at $25.44 on November 3, 2026 before the Q3 release, with 463,900 shares traded. Twenty completed sessions averaged 892,090 shares. Observed turnover provides a dated liquidity measure, while clinical and financing news can cause gaps and uneven fills. Price alone does not demonstrate executable depth or spreads.

Execution · 10%3.5

The randomized 253-patient mania Phase 2 trial met its week-three YMRS primary endpoint with a 3.1-point placebo-adjusted difference, p=0.045. FOCUS 1/2 enrollment and the completed financing support continued development. Pivotal replication, longer exposure, tolerability and capital discipline remain unresolved execution tests.

Reassessed November 4, 2026. Weighted calculation: 4.5 × 30% + 4.0 × 30% + 2.5 × 20% + 3.0 × 10% + 3.5 × 10% = 3.70 / 5. Financial and operational robustness over twelve to eighteen months; not an investment recommendation or a price target.

Red flags

  • RAP-219 remains investigational across indications.
  • The Phase 2 mania effect is statistically positive but needs pivotal replication.
  • Missing observations and discontinuations affect interpretation.
  • Open-label FOS follow-up differs from controlled pivotal evidence.
  • Multiple clinical programs increase spending and operational demands.
  • Long half-life can affect dosing, reversibility and safety management.
  • RAP-641 IND clearance differs from clinical efficacy or approval.
  • The November resource figure is an unaudited company estimate with a later measurement date.
  • End-2029 funding is a forecast with spending assumptions.
  • October financing increases the actual and potential share denominator.
  • Notes are physically settled in shares on conversion.
  • ATM sales occurred after September; future facility use remains possible.
  • Contingent Tenacia milestones differ from the upfront already received.

RAPP Stock FAQ: Rapport Therapeutics Questions Answered

When is the next RAPP stock catalyst?

As of November 4, 2026, Rapport expects initial long-term open-label focal-seizure safety data in Q4 2026. FOCUS 1 and FOCUS 2 are enrolling separately as controlled pivotal trials. Mania FDA discussions target Q1 2027, PGTCS Phase 3 initiation H1 2027 and two mania pivotal starts H2 2027. LAI pharmacokinetic data and RAP-641 early results have separate 2027 windows. These are company plans rather than exact readout or approval dates. Source.

Is Rapport’s RAP-219 FDA approved?

In its November 4, 2026 update, Rapport describes RAP-219 as investigational. Positive Phase 2 mania results support a planned Q1 2027 FDA discussion and two pivotal starts expected H2 2027, rather than marketing authorization. The FOCUS epilepsy trials are enrolling. Separately, RAP-641 IND clearance supports a planned Phase 1 trial; it is not product approval. Each indication and formulation requires its own adequate clinical and regulatory evidence. Source.

How much cash does Rapport have and what is its runway?

At September 30, 2026, Rapport reported $395.029 million cash and investments, excluding $0.105 million restricted cash. It separately estimates $815.4 million resources as of November 3 after later financing and forecasts funding through end-2029. The later estimate is not the filed September balance or an exact reconstructed interim cash bridge. Q3 operating cash use was $41.633 million, while trial costs and future plans can change funding requirements. Source. Filed September accounts.

Is RAPP stock exposed to dilution after the October financing?

At November 2, 2026, Rapport reported 59,279,630 actual common shares, versus 48,088,413 September 30. October financing added ordinary shares and 1,190,476 pre-funded warrants. The $172.5 million notes initially represent approximately 6.443 million conversion shares, with physical settlement under the closing terms. A further 399,201 ATM shares are separately disclosed. Weighted EPS shares, dated actual common shares and potential instruments are different ownership measures. Source. Physical-settlement closing terms.

When does Rapport report earnings next?

As of November 4, 2026, Rapport has not announced its next earnings date. The company released Q3 financials November 4: net loss $40.235 million, R&D $34.316 million and SG&A $9.770 million. It also updated financing and clinical milestones. The Q4 open-label safety window and planned 2027 trial or FDA events are distinct from a confirmed future financial-reporting date. Source.

What does Rapport Therapeutics do?

In its November 4, 2026 update, Rapport describes a clinical-stage precision-neuroscience company. RAP-219 selectively targets TARPγ8-associated AMPA receptor complexes and is being developed in focal seizures, bipolar mania and planned PGTCS studies. A long-acting injectable formulation and earlier RAP-641 pain/migraine program have separate development schedules. The company has no product sales; its nine-month collaboration revenue came from the Tenacia upfront rather than drug commercialization. Source.

Did Rapport complete its October offerings and private placement?

On October 30, 2026, Rapport closed public equity/pre-funded-warrant and convertible-note offerings together with a concurrent private placement. Underwriter options were exercised in full. The company reports approximately $410.7 million combined net proceeds, comprising $215.7 million equity, $166.8 million notes and $28.2 million private placement. The private placement issued 1,428,571 shares at $21. Later November ATM sales generated approximately $10 million gross and are separate transactions. Source.

How are Rapport’s new convertible notes settled?

Effective October 30, 2026, Rapport irrevocably fixed settlement of its 2.25% notes in common shares, with cash only for fractional shares. Holders may convert at their option until the contractual deadline before December 1, 2032 maturity. The initial rate is 37.3483 shares per $1,000 principal, approximately $26.775 per share. Issuer redemption and beneficial-ownership limits have separate contractual conditions; the final closing terms determine the settlement obligation. Source.

Primary sources

Market reference: Interactive Brokers TWS completed regular-session daily price and volume history through November 3, 2026, before Q3. Historical clinical and ownership analysis in the report keeps its original dates.

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $RAPP or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology companies carry clinical, regulatory, manufacturing, commercial and financing risks. Trials can fail, safety information can change and development timelines can slip. Additional borrowing or equity issuance can increase obligations or dilute shareholders. This page is not medical advice and does not replace a clinician or prescribing information. Investors can lose part or all of their capital. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.